Fresenius with clear analyst backing, shares hold near Xetra highs

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 13:45.

Fresenius (DE0005785604) enters the new trading week with a robust analyst backdrop. On Xetra the healthcare group’s shares recently traded around 39.8 euros, supported by several Buy ratings including a 55 euro target from Deutsche Bank in mid-June.

What analysts are saying

According to MarketScreener’s consensus overview, a clear majority of banks rate Fresenius as Buy or Outperform, with only a handful on Hold and virtually no major Sell recommendations reported for June 2026. The average 12?month target clusters in the low to mid?50 euro range, pointing to double?digit upside versus current levels.

Deutsche Bank reaffirmed its Buy stance on Fresenius on 16 June 2026 and set a price target of 55 euros, highlighting improving profitability and portfolio streamlining after past restructuring. Other houses such as UBS and Berenberg also remain constructive on German healthcare names, citing defensive earnings profiles compared with more cyclical DAX constituents, as recent sector comments on the broader healthcare space underline.

How the Fresenius shares trade

On Xetra, Fresenius shares recently changed hands at about 39.8 euros, after an intraday range between roughly 39.5 and 39.8 euros on 23 June 2026. Data from finanzen.net shows a last price of 39.81 euros at 09:55, up about 1.1 percent versus the previous day’s 39.37 euros.

Investing.com’s real?time derived quote for the FREG ticker also places the stock around 39.6 euros during Tuesday’s session, with the day’s range reported between 39.515 and 39.770 euros. This level keeps the shares within sight of their recent 12?month highs, though still below analyst targets in the 50 euro region.

How Fresenius earns its money

Fresenius generates revenue primarily from healthcare services and products, including hospital operations, dialysis care and intravenous drugs. The group’s Helios unit runs acute care hospitals in Germany and Spain, Kabi supplies clinical nutrition, IV generics and infusion therapies, and Vamed focuses on project management and services for healthcare facilities.

Where the shares trade today

The Fresenius shares (DE0005785604) trade on 2026-06-23, 09:55 on Xetra at 39.81 euros.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.